1. Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology. 2019;156:431–45.
2. Yao X, Sangaralingham LR, Ross JS, Shah ND, Talwalkar JA. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010–2014. Am J Manag Care. 2016;22:e224–32.
3. Rosenberg ES, Rosenthal EM, Hall EW, et al. Prevalence of hepatitis C virus infection in US States and the District of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1:e186371.
4. Reau N, Marx S, Manthena S, Strezewski J, Chirikov V. National examination of HCV linkage to care in the United States (2013-2016) based on large real-world dataset. Poster presentation at The Liver Meeting® 2018, November 09–13, 2018, San Francisco, CA, USA
5. Sulkowski M, Marx S, Manthena S, Strezewski J, Chirikov V. National estimates for HCV screening and diagnosis rates in the United States (2013-2016) based on large real-world dataset. Poster presentation at The Liver Meeting® 2018, November 09–13, 2018, San Francisco, CA, USA